CN113365659A - 抗pd-l1抗体治疗头颈癌的用途 - Google Patents

抗pd-l1抗体治疗头颈癌的用途 Download PDF

Info

Publication number
CN113365659A
CN113365659A CN202080011333.8A CN202080011333A CN113365659A CN 113365659 A CN113365659 A CN 113365659A CN 202080011333 A CN202080011333 A CN 202080011333A CN 113365659 A CN113365659 A CN 113365659A
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
chemotherapy
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080011333.8A
Other languages
English (en)
Other versions
CN113365659B (zh
Inventor
张喜全
王训强
陈杰
赵伟
陈德培
朱漫杰
魏娇
陈飞洋
周雅倩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Nanjing Shunxin Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Nanjing Shunxin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Nanjing Shunxin Pharmaceutical Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN113365659A publication Critical patent/CN113365659A/zh
Application granted granted Critical
Publication of CN113365659B publication Critical patent/CN113365659B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

本申请提供抗PD‑L1抗体治疗头颈癌的用途，其包括向所述主体施用治疗有效量的PD‑1受体和其配体PD‑L1之间的相互作用的抑制剂，其中抑制剂是抗PD‑L1抗体。

Description

PCT国内申请，说明书已公开。

Claims (42)

  1. PCT国内申请，权利要求书已公开。
CN202080011333.8A 2019-01-31 2020-01-31 抗pd-l1抗体治疗头颈癌的用途 Active CN113365659B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019100957345 2019-01-31
CN201910095734 2019-01-31
PCT/CN2020/074083 WO2020156500A1 (zh) 2019-01-31 2020-01-31 抗pd-l1抗体治疗头颈癌的用途

Publications (2)

Publication Number Publication Date
CN113365659A true CN113365659A (zh) 2021-09-07
CN113365659B CN113365659B (zh) 2023-08-18

Family

ID=71839951

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080011333.8A Active CN113365659B (zh) 2019-01-31 2020-01-31 抗pd-l1抗体治疗头颈癌的用途

Country Status (2)

Country Link
CN (1) CN113365659B (zh)
WO (1) WO2020156500A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023098798A1 (zh) * 2021-12-01 2023-06-08 正大天晴药业集团股份有限公司 用于治疗非小细胞肺癌的药物组合

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987405A (zh) * 2011-11-28 2014-08-13 默克专利股份公司 抗pd-l1抗体及其用途
WO2016022630A1 (en) * 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
WO2017011666A1 (en) * 2015-07-14 2017-01-19 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
CN107460221A (zh) * 2016-06-02 2017-12-12 正大天晴药业集团股份有限公司 一种降低抗pd‑l1抗体中蛋白聚合物的细胞培养方法
WO2018178040A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer
CN109153723A (zh) * 2016-05-13 2019-01-04 瑞泽恩制药公司 抗pd-1抗体与放射的组合治疗癌症

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016062722A1 (en) * 2014-10-24 2016-04-28 Astrazeneca Ab Combination
US11065332B2 (en) * 2015-11-04 2021-07-20 Duke University Combination therapy of immunotoxin and checkpoint inhibitor

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103987405A (zh) * 2011-11-28 2014-08-13 默克专利股份公司 抗pd-l1抗体及其用途
WO2016022630A1 (en) * 2014-08-05 2016-02-11 Jiping Zha Anti-pd-l1 antibodies
CN107001463A (zh) * 2014-08-05 2017-08-01 中美冠科生物技术（太仓）有限公司 抗pd‑l1抗体
WO2017011666A1 (en) * 2015-07-14 2017-01-19 Bristol-Myers Squibb Company Method of treating cancer using immune checkpoint inhibitor
CN107922502A (zh) * 2015-07-14 2018-04-17 百时美施贵宝公司 使用免疫检验点抑制剂治疗癌症的方法
CN109153723A (zh) * 2016-05-13 2019-01-04 瑞泽恩制药公司 抗pd-1抗体与放射的组合治疗癌症
CN107460221A (zh) * 2016-06-02 2017-12-12 正大天晴药业集团股份有限公司 一种降低抗pd‑l1抗体中蛋白聚合物的细胞培养方法
WO2018178040A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALFIERI等: "Immunotherapy for recurrent/metastatic head and neck cancer", 《CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY》, vol. 26, no. 2, pages 152 - 156 *
BAUML等: "Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study", 《JOURNAL OF CLINICAL ONCOLOGY:OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY》, vol. 35, no. 14, pages 1542 - 1549 *
CABEZAS-CAMARERO等: "Durable response to first-line nivolumab in a patient with oligometastatic PD-L1 positive nasopharyngeal cancer", 《ORAL ONCOLOGY》, vol. 87, pages 204 - 206, XP085559748, DOI: 10.1016/j.oraloncology.2018.10.019 *
SHETH等: "Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer", 《FUTURE ONCOLOGY》, vol. 14, no. 16, pages 11547 - 1558 *
毛璐等: "程序性细胞死亡受体-1与其配体信号通路的调控及其在头颈鳞状细胞癌治疗中的研究进展", 《国际口腔医学杂志》, vol. 45, no. 5, pages 560 - 565 *

Also Published As

Publication number Publication date
WO2020156500A1 (zh) 2020-08-06
CN113365659B (zh) 2023-08-18

Similar Documents

Publication Publication Date Title
CN107743401B (zh) 包含抗pd-1抗体和另外的抗体的组合的组合物
US20200262922A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
CA2955184A1 (en) Combination of an ox40 agonist and a 4-1bb agonist for treating cancer
US20160031990A1 (en) Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers
KR20160108568A (ko) 암을 치료하기 위한 pd-1 길항제 및 ido1 억제제의 조합
CN111973739B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
CN113365659B (zh) 抗pd-l1抗体治疗头颈癌的用途
US20240050564A1 (en) Combination therapy using an anti-fucosyl-gm1 antibody
US20240010729A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
WO2021155840A1 (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
CN113117072A (zh) 喹啉衍生物与pd-1单抗的药物组合
CN113164599B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
WO2023208001A1 (zh) 抗pd-1抗体和抗egfr抗体组合及其在治疗头颈部鳞癌中的用途
WO2023134787A2 (zh) 抗pd-1抗体和抗vegf抗体组合在治疗肝细胞癌中的用途
WO2024097896A1 (en) Methods for treating cancer using anti-ctla4 antibody in combination with pembrolizumab
WO2024050429A2 (en) Methods for treating cancer using anti-ctla4 antibodies
KR20230087451A (ko) 암 환자를 치료하기 위한 pd-1 길항제 및 vegfr-2에 대한 길항제의 조합 요법
CN116806226A (zh) 用于治疗癌症患者的pd-1拮抗剂和vegfr-2的拮抗剂的联合疗法
KR20170122809A (ko) 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant